DiaMedica Therapeutics Inc. (DMAC) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of DiaMedica Therapeutics Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NEO
NeoGenomics, Inc.
$16.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — DMAC vs NEO
growth of $100 · dividends reinvested · last 10yDMAC +113.7% (+7.9%/yr)NEO +134.5% (+8.9%/yr)NEO compounded faster over this window
DMAC NEO
DMAC vs NEO: by the numbers
- •DMAC is the larger company ($438M vs $424M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -6.77% net margin).
Metrics side by side
Valuation
| Metric | DMAC | NEO |
|---|---|---|
| Forward P/E | N/A | 90.32 |
| P/S ratio | N/A | 0.55 |
| P/B ratio | 11.43 | 0.54 |
Profitability
| Metric | DMAC | NEO |
|---|---|---|
| Gross margin | 0.00% | 42.92% |
| Operating margin | 0.00% | -8.63% |
| Net margin | 0.00% | -6.77% |
| ROE | -97.92% | -6.60% |
| ROIC | -100.87% | -5.29% |
Growth (annualized)
| Metric | DMAC | NEO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.41% |
| Total return CAGR (5Y) | 16.41% | -15.14% |
Frequently asked
- How have DMAC and NEO total returns compared?
- Over the past 10 years, DMAC delivered 7.89% and NEO delivered 8.90% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.